MedTrace Logo

First CORRECT Study of Minimal Residual Disease (MRD) Detection in Colorectal Cancer

NCT06398743 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 416

Last updated 2025-07-24

No results posted yet for this study

Summary

The CORRECT - MRD I study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Patients will be followed for up to 5 years for recurrence.

Conditions

Interventions

DEVICE

MRD

ctDNA MRD test

Sponsors & Collaborators

  • Fortrea

    collaborator INDUSTRY

  • Exact Sciences Corporation

    lead INDUSTRY

Principal Investigators

  • Somasundaram Subramaniam, MD · Exact Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-20
Primary Completion
2027-09-30
Completion
2027-12-31

Countries

  • Israel
  • Italy
  • Japan
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06398743 on ClinicalTrials.gov